Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-Directed IV Busulfan Conditioning for Lymphoma HSCT
NCT00948090Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of busulfan in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2010; status: completed.
02
Drugs
busulfan
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00948090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948090.